ADRB3 and metabolic disease: With mirabegron illustrating the most positive results for β3AR activation and associated metabolic outcomes, the agonist's ability to influence the inflammatory response associated with metabolic disorders was also investigated by the researchers (Jarc & Petan, 2020; Kälin et al., 2017).